Ensysce Biosciences, Inc. (ENSC) Press Releases https://ir.ensysce.com/news/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/ensysce/files/theme/images/logo-sm.png Ensysce Biosciences, Inc. Logo Equisolve Investor Relations Suite <![CDATA[Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study]]> https://ir.ensysce.com/news/press-releases/detail/216/ensysce-biosciences-secures-irb-approval-of-final-phase-of Thu, 16 Apr 26 08:00:00 -0400 https://ir.ensysce.com/news/press-releases/detail/216/ensysce-biosciences-secures-irb-approval-of-final-phase-of <![CDATA[Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs]]> https://ir.ensysce.com/news/press-releases/detail/215/ensysce-biosciences-secures-second-financing-from-2025 Tue, 07 Apr 26 08:00:00 -0400 https://ir.ensysce.com/news/press-releases/detail/215/ensysce-biosciences-secures-second-financing-from-2025 <![CDATA[Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results]]> https://ir.ensysce.com/news/press-releases/detail/214/ensysce-biosciences-reports-fourth-quarter-and-full-year Mon, 30 Mar 26 16:50:00 -0400 https://ir.ensysce.com/news/press-releases/detail/214/ensysce-biosciences-reports-fourth-quarter-and-full-year <![CDATA[Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans]]> https://ir.ensysce.com/news/press-releases/detail/213/ensysce-biosciences-initiates-live-ask-me-anything-ama Wed, 04 Mar 26 08:45:00 -0500 https://ir.ensysce.com/news/press-releases/detail/213/ensysce-biosciences-initiates-live-ask-me-anything-ama <![CDATA[Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology]]> https://ir.ensysce.com/news/press-releases/detail/212/ensysce-biosciences-announces-first-peer-reviewed-clinical Tue, 03 Mar 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/212/ensysce-biosciences-announces-first-peer-reviewed-clinical <![CDATA[Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value]]> https://ir.ensysce.com/news/press-releases/detail/211/ensysce-biosciences-initiates-review-of-strategic Wed, 25 Feb 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/211/ensysce-biosciences-initiates-review-of-strategic <![CDATA[Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events]]> https://ir.ensysce.com/news/press-releases/detail/210/ensysce-biosciences-invited-to-participate-in-upcoming Mon, 23 Feb 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/210/ensysce-biosciences-invited-to-participate-in-upcoming <![CDATA[Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain]]> https://ir.ensysce.com/news/press-releases/detail/209/ensysce-biosciences-provides-enrollment-update-on-pivotal Wed, 28 Jan 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/209/ensysce-biosciences-provides-enrollment-update-on-pivotal <![CDATA[Ensysce Biosciences Expands Global Opioid Patent Portfolio]]> https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio Wed, 21 Jan 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio <![CDATA[Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection]]> https://ir.ensysce.com/news/press-releases/detail/207/ensysce-biosciences-receives-eu-patent-expanding-its Thu, 08 Jan 26 08:00:00 -0500 https://ir.ensysce.com/news/press-releases/detail/207/ensysce-biosciences-receives-eu-patent-expanding-its